TEP1

Across TCGA pan-cancer cohorts, TEP1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TEP1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TEP1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TEP1 is over-expressed in tumor, although a few such as COAD and OV show the opposite, repressed pattern.

CCRCC, PDAC, and COAD are the cancer types where TEP1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TEP1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.435	<.001	12	view →
PDAC	Female	All	+0.489	<.001	10	view →
COAD	Female	All	−0.340	<.001	10	view →
HNSC	Male	II,III,IV	+0.240	<.001	8	view →
LUAD	Female	All	+0.307	<.001	6	view →
OV	All	All	−0.348	.042	2	view →
LSCC	Male	All	−0.100	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TEP1–CCRCC

Open the CCRCC breakdown →